1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow HELLP Syndrome: new trials by email Literature Review of HELLP Syndrome trials Research Report on HELLP Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Complement Regulation to Undo Systemic Harm in Preeclampsia Eculizumab - Preeclampsia, Severe Preeclampsia | Phase 2 | Terminated | Cedars-Sinai Medical Center | 2 | 2021-09-13 | 2023-11-29 |
| Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial labetalol (seizure prevention), MgSO4 (seizure prevention) - Preeclampsia, Pregnancy Induced Hypertension | Phase 2 / Phase 3 | Withdrawn | Baylor College of Medicine | 2015-06-01 | 2017-01-13 |
Pre-Eclampsia (2) · Eclampsia (1) · Hypertension (1) · Hypertension, Pregnancy-Induced (1) · Seizures (1)
Female Urogenital Diseases and Pregnancy Complications (2) · Pregnancy Complications (2) · Urogenital Diseases (2) · Cardiovascular Diseases (1) · Hypertension, Pregnancy-Induced (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Vascular Diseases (1)
Labetalol (1) · eculizumab (1)
Baylor College of Medicine (1) · Cedars-Sinai Medical Center (1)
United States (2) · India (1)
Michael A Belfort, MD, PhD (1) · Richard Burwick, MD, MPH (1)